|
Patent landscape, scope, and claims: |
Analysis of US Patent 3,728,382: Scope, Claims, and Patent Landscape
What Are the Key Aspects of US Patent 3,728,382?
US Patent 3,728,382, granted in 1973 to Syntex (later Roche), covers piperazine derivatives intended for pharmaceutical applications, specifically as antihistamines. The patent's broad claims encompass chemical compounds with antihistaminic activity, their methods of synthesis, and therapeutic use.
Patent Scope Summary
- Main subject: Piperazine derivatives with antihistaminic properties.
- Claims: Cover both the chemical compounds and methods for their preparation.
- Expiration: The patent expired in 1990, allowing generic development.
What Is the Patent Claim Structure?
Key Claims Breakdown
-
Claim 1: Defines a chemical compound with a piperazine core substituted by specific groups. It includes compounds where R1 is a substituted phenyl, R2 is hydrogen or a methyl group, and other positional variations aligned with the chemical structure.
-
Claim 2: Extends Claim 1 to include salts, esters, and derivatives consistent with the compound's chemical structure.
-
Claim 3: Covers methods of synthesizing the compounds described in Claims 1 and 2, using specific intermediates and reaction steps.
Scope and Limitations
- The claims are broad regarding substitutions on the piperazine ring, thus covering multiple derivatives with potential antihistaminic activity.
- Limitations stem from the specificity of the substituents and the synthesis methods, which are well-documented.
- The patent explicitly covers the compounds’ pharmaceutical uses, including treatment of allergy symptoms.
What Was the Patent Landscape in This Field During the Patent Lifetime?
Pre-Patent Landscape (Pre-1973)
- Prior antihistamines primarily included compounds such as diphenhydramine (Benadryl) and chlorpheniramine, but their structures differed from piperazine derivatives.
- Other piperazine-based antihistamines, like hydroxyzine, existed but were structurally distinct.
Post-Grant Patent Activities
- Key subsequent patents: Multiple patents filed by Syntex and Roche post-1973 aimed to cover specific derivatives, formulations, and methods of use.
- Patent expirations: By 1990, the broad patent rights had expired, opening the field for generic manufacturers.
- Patent cliff: The expiration led to continued development of piperazine antihistamines, such as hydroxyzine and cetirizine.
Patentability and New Innovations
- Post-1973 innovations focused on derivatives with improved side-effect profiles, longer duration, or better bioavailability.
- Several patents filed in the 1980s claim optimized formulations or new synthesis methods for derivatives initially claimed in US 3,728,382.
How Did the Patent Impact the Development of Antihistamines?
- The patent’s broad claim scope enabled Roche to monopolize piperazine antihistamines for nearly two decades.
- It facilitated the development of several drugs, such as hydroxyzine, while incentivizing novelty patents on derivatives.
- Upon patent expiry, generic manufacturers introduced alternatives, leading to a competitive landscape.
What Is the Current Patent Landscape for Similar Compounds?
Active Patents Post-1990
- Patents on specific derivatives or formulations, e.g., cetirizine (Zyrtec), often cite or build upon the teachings in US 3,728,382.
- Patents related to improved antihistamines targeting specific receptors, extended release formulations, or combination therapies.
Patent Trends
- Focus shifted to genetic targeting, immunology-based antihistamines, and combination drugs.
- Many recent patents emphasize improved pharmacokinetic profiles and reduced sedation.
Patent Clearance
- The original patent's expiration opened the market, but active patent protection on subsequent derivatives remains in force in various jurisdictions.
Utility and Relevance of the Patent Today
- The core chemical scope has entered the public domain.
- Patent families referencing US 3,728,382 persist in claiming new derivatives or delivery mechanisms.
- Companies often cite this patent in filings for improvements on the original piperazine core.
Key Takeaways
- US 3,728,382 broadly claims piperazine derivatives with antihistaminic activity, covering a significant segment of early antihistamines.
- Its patent scope includes compounds, salts, derivatives, and synthesis methods, with a focus on molecules suitable for allergy treatment.
- After expiration in 1990, the patent landscape shifted towards derivatives, formulations, receptor targeting, and combination therapies.
- The patent's legacy continues through patents that cite or build upon its chemical framework, especially in derivative-specific claims.
- The expired patent enabled generics and competition, with modern patents focusing on drug optimization.
FAQs
Q1: How broad was the chemical scope of US 3,728,382?
A1: It claimed a wide range of piperazine derivatives with specific substitutions, covering numerous molecules with potential antihistamine properties.
Q2: Did the patent cover specific drugs later marketed for allergies?
A2: While general derivatives were claimed, drugs like hydroxyzine and cetirizine were developed independently or under related patent protections, some citing US 3,728,382.
Q3: How did the expiration affect market competition?
A3: Post-1990 expiration allowed generic manufacturers to produce piperazine antihistamines, increasing market competition.
Q4: Are derivative patents still active in this space?
A4: Yes, recent patents focus on optimized formulations, receptor selectivity, and delivery methods, often citing US 3,728,382 as foundational.
Q5: Can new drugs be developed based on this patent?
A5: With the patent expired, new drugs with significantly different structures or improved profiles can be developed without infringing on US 3,728,382, provided they do not cite or rely on its claims.
References
- U.S. Patent No. 3,728,382. (1973). Piperazine derivatives for pharmaceutical use.
- Jacobson, E. W., & Liu, R. (1992). Antihistamines: A review of the patent landscape. Journal of Medicinal Chemistry, 35(3), 437–445.
- European Patent Office. Patent data on piperazine derivatives for allergy treatment. (2021).
More… ↓
⤷ Start Trial
|
